2019 Press Releases Communiqués de presse
Sernova Renews Frontier Flex for Canadian Investor Relations and Marketing
Sernova Completes Oversubscribed Private Placement of $4,684,564
Sernova Announces Second Closing of Private Placement
Sernova Announces First Closing of Private Placement
Sernova Announces Up to $3 Million Private Placement Financing
Sernova Phase I/II US Clinical Trial for Type-1 Diabetes Advances Following Positive Preliminary Safety and Efficacy Data
Sernova Corp Presents Positive Preliminary Safety and Efficacy Data in its Phase I/II Clinical Trial for Type-1 Diabetes
Sernovas Principal Investigator to Present Interim Data from the Companys Ongoing Phase I/II Cell Pouch Clinical Trial at the 17th World Congress of t
Sernova Corp Announces Appointment of Deborah Brown to its Board of Directors
Sernova Announces Collaboration to Advance Therapeutic Cell Pouch Technologies for the Treatment of Hypothyroidism
Sernova Announces First Transplantation of Therapeutic Cells in Cell Pouch for the Company Phase I/II U.S. Clinical Study for Diabetes
Sernova Corp Announces First Patient Implanted with Sernova Cell Pouch in a Phase I/II US Clinical Trial for the Treatment of Hypoglycemia Unawareness
Sernova Announces the Appointment of Dr. David Lillicrap, M.D. to its Scientific Advisory Board
Sernova to Participate on Diabetes Panel and Present at NobleConXV, 15th Annual Investor Conference January 28th - 29th, 2019
Sernova Announces Successful Enrollment Approaching 50% of Subjects in its U.S. Phase I/II Cell Pouch Diabetes Clinical Trial
Share the news Partagez les nouvelles
Press Release Communiqué de presse - September 17, 2019 17 September, 2019
Sernova Renews Frontier Flex for Canadian Investor Relations and Marketing
Source: Sernova Corp
September 17, 2019, 9:00 a.m. EDT
LONDON, ONTARIO – September 17, 2019– Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a
clinical-stage regenerative medicine company, announces that it has renewed the engagement of Frontier Flex,
an investor relations (IR) and marketing group based in Toronto, Ontario Canada to provide Canadian IR and
strategic marketing services.
Sernova President and CEO Dr. Philip Toleikis commented, "Frontier remains an integral part of the
communications strategy Sernova is implementing to increase Sernova’s visibility and help investors and
shareholders stay well-informed as we advance our clinical programs including our US diabetes Phase I/II
clinical study.”
Through their established network of financial industry professionals, marketing service providers, and
outreach programs, FronTier will assist the corporation by increasing market awareness for the corporation
using a number of financial market communications initiatives, including facilitating in-person introductions for
the corporation with institutional and retail brokers in Toronto and other financial capitals, and through media
distribution on national television, radio and multiple online channels.
Under the terms of the engagement, FronTier has been retained for a 12-month period for aggregate
remuneration of $100,000 plus expenses. The agreement with Frontier Flex is subject to the approval of the
TSX Venture Exchange.
In other news, Sernova has granted 6,980,000 stock options to certain officers, employees, and consultants of
the company, each such option being exercisable into one common share at a price of $0.21 per share for
periods ranging from 3 to 10 years, and has granted 3,120,167 DSUs to its directors.
About Sernova Corp
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells to improve the treatment and quality of life of people with chronic metabolic
diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated
through replacement of proteins or hormones missing or in short supply within the body. For more information,
please visit www.sernova.com
For further information contact:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
Fax: (519) 858-5099
Toll-Free: (877)-299-4603
dominic.gray@sernova.com
www.sernova.com
Forward-Looking Information7
This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,
“believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions
“will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of
future performance, and actual results may differ materially from those in forward-looking statements.
Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the
date such statements were made, which include our belief about the conduct and outcome of clinical trials.
Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements
whether as a result of new information, future events or otherwise.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - September 10, 2019 10 September, 2019
Sernova Completes Oversubscribed Private Placement of $4,684,564
Source: Sernova Corp
September 10, 2019 9:00 a.m. EDT
LONDON, ONTARIO –September 10, 2019 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH)
announces it has completed on Monday a non-brokered private placement of $4.685 million, pursuant to which
Sernova issued a total of 23,422,822 Units in three closings (August 16, 2019, August 30, 2019 and September
9, 2019).
Net proceeds from the private placement will be used to support funding of Sernova's clinical program
including its FDA cleared US Phase I/II regenerative medicine clinical trial, “Safety, Tolerability and Efficacy
Study of Sernova’s Cell Pouch(TM) for Clinical Islet Transplantation” and to advance internal preclinical
development programs and corporate/academic collaborations utilizing the Company’s platform technologies
to treat diabetes, hemophilia and other serious disease conditions, as well as for investor relations and general
corporate purposes.
Each Unit in the Offering is priced at $0.20 per Unit and consists of one common share and one common share
purchase warrant (“Warrant”). Each Warrant will be exercisable into one share at a price of $0.30 per share for
a period of 36 months.
The private placement has received approval of the TSX Venture Exchange. Pursuant to applicable Canadian
securities laws, the securities issued under the Private Placement are subject to a four-month hold period from
the time of closing of the Private Placement. The hold periods for this Private Placement expire on December
17, 2019, December 31, 2019, and January 10, 2020.
The Company compensated finders by way of cash fees of $78,225 and 391,125 non-transferable finder
warrants, each such finder warrant having the same terms as the Unit warrants.
About Sernova’s US Clinical Study
The approved protocol is a Phase I/II non-randomized, unblinded, single-arm, company-sponsored trial, where
diabetic subjects with hypoglycemia unawareness enroll into the study. Participants are then implanted with
Cell Pouches. Following the development of vascularized tissue chambers within the Cell Pouch, subjects are
then stabilized on immunosuppression, and a dose of purified islets, under strict release criteria, is
transplanted into the Cell Pouch.
A sentinel pouch is removed for an early assessment of the islet transplant. Subjects will be followed for
additional safety and efficacy measures for approximately six months. At this point, a decision will be made
with regards to the transplant of a second islet dose with subsequent safety and efficacy follow up. Patients will
then be further followed for one year. The primary objective of the study is to demonstrate safety and
tolerability of islet transplantation into the Cell Pouch. The secondary objective is to assess efficacy through a
series of defined measures.
For more information on this clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939. For more
information on enrollment and recruitment details, please visit www.pwitkowski.org/sernova.
About Sernova Corp
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells to improve the treatment and quality of life of people with chronic metabolic
diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated
through replacement of proteins or hormones missing or in short supply within the body. For more information,
please visit www.sernova.com
For further information contact:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
Fax: (519) 858-5099
Toll-Free: (877)-299-4603
dominic.gray@sernova.com
www.sernova.com
Forward-Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,
“believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions
“will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of
future performance, and actual results may differ materially from those in forward-looking statements.
Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the
date such statements were made, which include our belief about the conduct and outcome of clinical trials.
Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements
whether as a result of new information, future events or otherwise.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - September 03, 2019 3 September, 2019
Sernova Announces Second Closing of Private Placement
THIS NEWS RELEASE IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR
DISSEMINATION IN THE UNITED STATES.
September 3, 2019 9:00 a.m. EDT
LONDON, ONTARIO – September 3, 2019 – Sernova Corp. (TSX-V:SVA) (FSE:PSH) (OTCQB:SEOVF), a clinical-
stage regenerative medicine company, is pleased to announce that it has completed a second closing of
$2,251,065 of its non-brokered private placement, (announced on July 25, 2019) of which an additional
$67,400 was closed under the “Existing Shareholder Exemption.” Total proceeds to date are $4,584,565.
In addition, the Company announces that it is increasing the maximum offering, for a total of up to $5,500,000
of Units. Each Unit in the Offering is priced at $0.20 per Unit and consists of one common share and one
common share purchase warrant (“Warrant”). Each Warrant will be exercisable into one share at a price of
$0.30 per share for a period of 36 months.
The Company plans to close the balance of the placement later this week.
Net proceeds from the increased portion of the private placement will be used to support funding of Sernova's
clinical program including its FDA cleared US Phase I/II regenerative medicine clinical trial and to advance
corporate/academic collaborations utilizing the Company’s platform technology to treat diabetes, hemophilia
and other serious disease conditions, as well as for investor relations and general corporate purposes.
Completion of the private placement is subject to the approval of the TSX Venture Exchange. All securities
issued in connection with the private placement will be subject to a statutory hold period of four months.
This news release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities
in the United States. The securities have not been and will not be registered under the U.S. Securities Act of
1933 or any state securities laws, and may not be offered or sold in the United States without registration
under the U.S. Securities Act of 1933 and all applicable state securities laws, or an applicable exemption from
registration requirements.
ABOUT SERNOVA’S US CLINICAL STUDY
The approved protocol is a Phase I/II non-randomized, unblinded, single-arm, company-sponsored trial, where
diabetic subjects with hypoglycemia unawareness enroll into the study. Participants are then implanted with
Cell Pouches. Following the development of vascularized tissue chambers within the Cell Pouch, subjects are
then stabilized on immunosuppression, and a dose of purified islets, under strict release criteria, is
transplanted into the Cell Pouch.
A sentinel pouch is removed for an early assessment of the islet transplant. Subjects will be followed for
additional safety and efficacy measures for approximately six months. At this point, a decision will be made
with regards to the transplant of a second islet dose with subsequent safety and efficacy follow up. Patients will
then be further followed for one year. The primary objective of the study is to demonstrate safety and
tolerability of islet transplantation into the Cell Pouch. The secondary objective is to assess efficacy through a
series of defined measures.
For more information on this clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939. For more
information on enrollment and recruitment details, please visit www.pwitkowski.org/sernova.
ABOUT SERNOVA CORP.
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e. human donor cells, corrected human cells and stem-cell-derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent
diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or
hormones missing or in short supply within the body. For more information, please visit www.sernova.com
For further information, please contact:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
FAX: (519) 858-5099
Toll-Free: (877)-299-4603
dominic.gray@sernova.com
www.sernova.com
FORWARD-LOOKING INFORMATION
This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,
“believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions
“will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of
future performance, and actual results may differ materially from those in forward-looking statements.
Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the
date such statements were made, which include our beliefs about the conduct and outcome of clinical trials.
Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements
whether as a result of new information, future events or otherwise.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - August 19, 2019 19 August, 2019
Sernova Announces First Closing of Private Placement
Offering Increased to $3,500,000
THIS NEWS RELEASE IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR
DISSEMINATION IN THE UNITED STATES.
August 19, 2019 9:00 a.m. EDT
LONDON, ONTARIO – August 19, 2019 – Sernova Corp. (TSX-V:SVA) (FSE:PSH) (OTCQB:SEOVF), a clinical-
stage regenerative medicine company, is pleased to announce that it has completed a first closing of
$2,333,500 of its non-brokered private placement, (which was announced on July 25, 2019), of which $64,000
was closed under the “Existing Shareholder Exemption.”
In addition, the Company announces that it is increasing the maximum offering by an additional $500,000, for a
total offering of $3,500,000 of Units. Each Unit in the Offering is priced at $0.20 per Unit and consists of one
common share and one common share purchase warrant (“Warrant”). Each Warrant will be exercisable into
one share at a price of $0.30 per share for a period of 36 months.
The Company plans to close the balance of the placement in the coming weeks.
Net proceeds from the increased portion of the private placement will be used to support funding of Sernova's
clinical program including its FDA cleared US Phase I/II regenerative medicine clinical trial and to advance
corporate/academic collaborations utilizing the Company’s platform technology to treat diabetes, hemophilia
and other serious disease conditions, as well as for investor relations and general corporate purposes.
Completion of the private placement is subject to the approval of the TSX Venture Exchange. All securities
issued in connection with the private placement will be subject to a statutory hold period of four months.
This news release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities
in the United States. The securities have not been and will not be registered under the U.S. Securities Act of
1933 or any state securities laws, and may not be offered or sold in the United States without registration
under the U.S. Securities Act of 1933 and all applicable state securities laws, or an applicable exemption from
registration requirements.
ABOUT SERNOVA’S US CLINICAL STUDY
The approved protocol is a Phase I/II non-randomized, unblinded, single-arm, company-sponsored trial, where
diabetic subjects with hypoglycemia unawareness enroll into the study. Participants are then implanted with
Cell Pouches. Following the development of vascularized tissue chambers within the Cell Pouch, subjects are
then stabilized on immunosuppression, and a dose of purified islets, under strict release criteria, is
transplanted into the Cell Pouch.
A sentinel pouch is removed for an early assessment of the islet transplant. Subjects will be followed for
additional safety and efficacy measures for approximately six months. At this point, a decision will be made
with regards to the transplant of a second islet dose with subsequent safety and efficacy follow up. Patients will
then be further followed for one year. The primary objective of the study is to demonstrate safety and
tolerability of islet transplantation into the Cell Pouch. The secondary objective is to assess efficacy through a
series of defined measures.
For more information on this clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939. For more
information on enrollment and recruitment details, please visit www.pwitkowski.org/sernova.
ABOUT SERNOVA CORP.
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e. human donor cells, corrected human cells and stem-cell-derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent
diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or
hormones missing or in short supply within the body. For more information, please visit www.sernova.com
For further information, please contact:
Canada:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
FAX: (519) 858-5099
Toll-Free: (877)-299-4603
dominic.gray@sernova.com
www.sernova.com
FORWARD-LOOKING INFORMATION
This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,
“believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions
“will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of
future performance, and actual results may differ materially from those in forward-looking statements.
Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the
date such statements were made, which include our beliefs about the conduct and outcome of clinical trials.
Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements
whether as a result of new information, future events or otherwise.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - July 25, 2019 25 July, 2019
Sernova Announces Up to $3 Million Private Placement Financing
THIS NEWS RELEASE IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR
DISSEMINATION IN THE UNITED STATES.
Source: Sernova Corp
July 25, 2019 8:30 a.m. EDT
LONDON, ONTARIO – July 25, 2019 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH) announces a
proposed private placement (the “Offering”) of up to $3 million in units (the “Units”) of the Company at a price
of $0.20 per Unit including up to $1 million in Units that are being offered pursuant to the “existing shareholder
prospectus exemption.”
Each Unit in the Offering will consist of one common share and one common share purchase warrant
(“Warrant”). Each Warrant will be exercisable into one share at a price of $0.30 per share for a period of 36
months.
Terms Relating to the Existing Shareholder Exemption
The Company is pleased to invite existing shareholders who qualify under the “existing shareholder prospectus
exemption” to participate in the Offering.
The criteria of the “existing shareholder prospectus exemption” (the “Existing Shareholder Exemption”) are set
out in various regulatory instruments of the participating jurisdictions in Canada. To comply with the criteria of
the Existing Shareholder Exemption, the offering will be subject to, among other criteria, the following:
• The subscriber must be a shareholder as of July 24, 2019, which has been set as the record date (the
“Record Date”) for the purpose of determining existing shareholders entitled to purchase shares pursuant to the
Existing Shareholder Exemption.
• To participate, a qualified shareholder must deliver (a) an executed subscription agreement in the required
form, which will include requirements of the Existing Shareholder Exemption (e.g., that the subscriber was as of
the Record Date and continues to be as of the date of closing, a shareholder of Sernova) and (b) pay the
subscription amount no later than August 16, 2019. Contact information to obtain the subscription form is set
out below.
• The aggregate acquisition cost to a subscriber under the Existing Shareholder Exemption cannot exceed
$15,000 unless that subscriber has obtained advice from a registered investment dealer regarding the
suitability of the investment.
• A maximum of $1 million of Units (“Maximum”) will be offered to shareholders as of the Record Date under
the Existing Shareholder Exemption. There is no minimum amount in the Offering.
• If subscriptions received from shareholders who qualify under the Existing Shareholder Exemption exceed
the Maximum, each such subscriber will be allocated Units in proportion to each such qualified shareholder’s
share ownership as of the Record Date, or the additional subscriptions may be accepted (by increasing the
Maximum) at the discretion of the Company.
• If subscriptions received for the Offering based on all available exemptions exceed the total amount of the
Offering (after the fulfilment of subscriptions from existing shareholders), subscriptions may be accepted (by
increasing the Offering size) at the discretion of the Company.
• In accordance with the Existing Shareholder Exemption, the Company confirms there is no material fact or
material change related to the Company that has not been generally disclosed.
Further terms and conditions shall be set out in the form of subscription agreement that will be made available
to interested shareholders, who are directed to contact the Company as follows:
Contact Person: Dominic Gray
Tel: 1 (519) 858 5126
Fax: 1 (519) 858 5099
Toll-Free: 1 (877) 299 4603
email: dominic.gray@sernova.com
Assuming the Offering is fully subscribed, the Corporation plans to allocate the gross proceeds as follows: (i)
$2 million for development of Sernova’s Cell Pouch technologies including advancing Sernova's US-based
Phase I/II diabetes clinical trial, potential collaborations utilizing our Cell Pouch System platform technologies,
and preclinical programs including haemophilia, hypothyroid disease and our advanced diabetes stem cell
program and (ii) up to $210,000 for cash finders’ compensation, assuming such fees are paid on the entire
amount, and (iii) the balance for general corporate purposes.
If the Offering is not fully subscribed, the Company will apply the proceeds to the above uses in priority and in
such proportions as the Board of Directors and management of the Company determine is in the best interests
of the Company. Although the Company intends to use the proceeds of the Offering as described above, the
actual allocation of proceeds may vary from the uses set out above depending on future operations, events, or
opportunities.
All securities issued in connection with the private placement will be subject to a statutory hold period of four
months. The Company will compensate finders on a portion of the private placement, such compensation
consisting of 7% in cash or 7% in finder warrants, or a combination thereof. Completion of the private
placement is subject to the receipt of all necessary corporate and regulatory approvals, including approval of
the TSX Venture Exchange.
Certain insiders of the Company are expected to participate in the Offering (the "Insider Participation"), which
will be considered a related party transaction within the meaning of Multilateral Instrument 61-101 ("MI 61-
101"). Sernova intends to rely on the exemptions from the valuation and minority shareholder approval
requirements of MI 61-101 contained in Sections 5.5(a) and 5.7(1)(a) of MI 61-101 in respect of any Insider
Participation.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in
the United States. The securities have not been and will not be registered under the United States Securities Act
of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold
within the United States unless registered under the U.S. Securities Act and applicable state securities laws or
an exemption from such registration is available.
About the US Clinical Study
The approved protocol is a Phase I/II non-randomized, unblinded, single-arm, company-sponsored trial, where
diabetic subjects with hypoglycemia unawareness are enrolled into the study. Participants are then implanted
with Cell Pouches. Following the development of vascularized tissue chambers within the Cell Pouch, subjects
are then stabilized on immunosuppression, and a dose of purified islets, under strict release criteria, is
transplanted into the Cell Pouch.
A sentinel pouch is removed for an early assessment of the islet transplant. Subjects are followed for additional
safety and efficacy measures for approximately six months. At this point, a decision is made with regards to the
transplant of a second islet dose with subsequent safety and efficacy follow up. Patients are then further
followed for one year. The primary objective of the study is to demonstrate safety and tolerability of islet
transplantation into the Cell Pouch. The secondary objective is to assess efficacy through a series of defined
measures.
For more information on this clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939. For more
information on enrollment and recruitment details, please visit www.pwitkowski.org/sernova.
About Sernova Corp
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e. human donor cells, corrected human cells and stem-cell-derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent
diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or
hormones missing or in short supply within the body. For more information, please visit www.sernova.com
For further information contact:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
Forward-Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,
“believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions
“will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of
future performance, and actual results may differ materially from those in forward-looking statements.
Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the
date such statements were made, which include our belief about the conduct and outcome of clinical trials and
that Sernova will be able to raise additional capital to fund its clinical programs including its ongoing US FDA
clinical trial. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking
statements whether as a result of new information, future events or otherwise.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - July 17, 2019 17 July, 2019
Sernova Phase I/II US Clinical Trial for Type-1 Diabetes Advances Following Positive Preliminary Safety and Efficacy Data
CEO to participate in conference call with Sernova Shareholders on July 18 at 10:00 am (EDT)
July 17, 2019 3:05 a.m. EDT
LONDON, ONTARIO – July 17, 2019 – Sernova Corp. (TSX-V:SVA) (FSE:PSH) (OTCQB:SEOVF), a clinical-stage
regenerative medicine company today announced that its human Phase I/II clinical trial for type-1 diabetes is
advancing with additional patients for device and cell transplantation.
Sernova announced on July 3, 2019, a case study describing preliminary data from its current clinical trial: A
Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch for Clinical Islet Transplantation. Sernova’s Cell
Pouch transplanted with islet cells demonstrated initial safety, as well as key efficacy measures, including
glucose-stimulated blood levels of C-peptide, insulin, and additional measures of glucose control in the first
study patient with type-1 diabetes and severe hypoglycemia unawareness.
A summary of the data presented at the International Pancreas and Islet Transplantation Association (IPITA)
World Congress is as follows:
• No incidences of adverse events determined to be related to the Cell Pouch implant.
• The Cell Pouch was well-incorporated with vascularized tissue, which enabled successful transplant of the
purified islets
• A reduction in body weight
• Stabilizing improvements in glycemic control parameters measured by Continuous Glucose Monitoring
(CGM), assessed by Medtronic
• 87.5% reduction in hypoglycemic events from baseline collected over a two-week CGM monitoring period
• Presence of stimulated blood levels of C-peptide and insulin at the observed 90-day post-transplant point
as indicated in a mixed meal tolerance test
“I am pleased with these interim results in the first implanted patient,” said Dr. Piotr Witkowski, Director of
Pancreatic, and Islet Transplant Program at the University of Chicago and study principal investigator. “The first
dose of islets transplanted into the Cell Pouch has shown safety and early indicators of potential efficacy. We
found some glucose-stimulated C-peptide and insulin present in the bloodstream, which are the gold standard
indicators of islet function. Our team continues the research and looks forward to reporting longer-term results
in additional patients as the trial progresses.”
“The preliminary clinical data achieved in this patient with our pre-vascularized implanted Cell Pouch
represent an early clinical validation for our regenerative medicine technologies as we pursue safe, efficacious,
and transformative treatments for patients with hypoglycemia unawareness in type-1 diabetes,” said Dr. Philip
Toleikis, President and CEO of Sernova Corp. “With these data from our current clinical trial, in conjunction
with our advancing hemophilia A, hypothyroid, and diabetes stem cell programs, we believe Sernova is closer
to achieving significant advancements in regenerative medicine treatment.”
The Company continue actively recruiting and enrolling subjects and is expecting to report further data from
Sernova’s clinical study in the second half of 2019.
Dr. Toleikis will participate in a conference call with Sernova shareholders at 10:00 am (ET) on July 18 to
discuss the recently announced trial data as well as the corporate updates. A presentation will be made
available on Sernova’s website before the call. All questions to Dr. Toleikis can be submitted to
info@sernova.com prior to the call. To participate in this live conference call, please dial:
• US Toll-Free: + 1-877-366-0711
• Canada Toll-Free: + 1-866-627-1651
• Int’l Toll-Free: + 1-302-709-8446
The conference participant passcode is 109 985 50. Following the conference call a recording will be available
at www.sernova.com
ABOUT THE US CLINICAL STUDY
The approved protocol is a Phase I/II non-randomized, unblinded, single-arm, company-sponsored trial, where
diabetic subjects with hypoglycemia unawareness enroll into the study. Participants are then implanted with
Cell Pouches. Following the development of vascularized tissue chambers within the Cell Pouch, subjects are
then stabilized on immunosuppression, and a dose of purified islets, under strict release criteria, is
transplanted into the Cell Pouch.
A sentinel pouch is removed for an early assessment of the islet transplant. Subjects will be followed for
additional safety and efficacy measures for approximately six months. At this point, a decision will be made
with regards to the transplant of a second islet dose with subsequent safety and efficacy follow up. Patients will
then be further followed for one year. The primary objective of the study is to demonstrate safety and
tolerability of islet transplantation into the Cell Pouch. The secondary objective is to assess efficacy through a
series of defined measures.
For more information on this clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939. For more
information on enrollment and recruitment details, please visit www.pwitkowski.org/sernova.
ABOUT SERNOVA CORP.
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e. human donor cells, corrected human cells and stem-cell-derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent
diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or
hormones missing or in short supply within the body. For more information, please visit www.sernova.com
For further information, please contact:
United States:
Danny Matthews
Solebury Trout
Tel: (646) 378-2928
dmatthews@soleburytrout.com
www.soleburytrout.com
Canada:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
FORWARD-LOOKING INFORMATION
This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,
“believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions
“will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of
future performance, and actual results may differ materially from those in forward-looking statements.
Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the
date such statements were made, which include our beliefs about the conduct and outcome of clinical trials.
Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements
whether as a result of new information, future events or otherwise.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - July 03, 2019 3 July, 2019
Sernova Corp Presents Positive Preliminary Safety and Efficacy Data in its Phase I/II Clinical Trial for Type-1 Diabetes
Sernova’s Cell Pouch (TM) with transplanted islet cells reached primary safety measurements and clinically
significant efficacy outcomes including glucose-stimulated C-peptide and the release of insulin in the first
patient transplanted
July 3, 2019 5:30 a.m. EDT
LONDON, ONTARIO – July 3, 2019 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF), a clinical-stage regenerative
medicine company today announced that in an interim analysis of its human Phase I/II clinical trial, Sernova’s
Cell Pouch transplanted with islet cells showed initial safety, as well as key efficacy measures, including glucose
stimulated C-peptide, insulin production and additional clinically significant measures of glucose control in the
first study patient with type-1 diabetes and severe hypoglycemia unawareness.
Dr. Piotr Witkowski, Director of Pancreatic, and Islet Transplant Program at the University of Chicago and study
principal investigator presented on Sernova’s Cell Pouch technology and preliminary data from Sernova’s
current clinical trial: A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch for Clinical Islet
Transplantation today at the 17th World Congress of the International Pancreas and Islet Transplantation
Association (IPITA) in Lyon, France.
Highlights of the presentation of the data from the first patient who received islet transplanted into Sernova
Cell Pouch included:
• No incidences of adverse events determined to be related to the Cell Pouch implant.
• The Cell Pouch was well-incorporated with vascularized tissue, which enabled successful transplant of the
purified islets
• A weight reduction of 6.35kg (12% total body weight)
• Stabilizing improvements in all glycemic control parameters as indicated by Continuous Glucose
Monitoring (CGM) as assessed by Medtronic
• 87.5% reduction in hypoglycemic events from baseline collected over a two-week monitoring period
• Presence of stimulated blood levels of C-peptide and insulin at the observed 90-day post-transplant point
as indicated in a mixed meal tolerance test
“I am quite pleased with these interim results in the first implanted patient,” said Dr. Witkowski. “The first of
two doses of islets transplanted into the Cell Pouch is showing safety and early indicators of efficacy.
Importantly, demonstration of glucose-stimulated C-peptide and insulin present in the bloodstream is
definitive proof of islet survival and function in the Cell Pouch. These results are an important first step towards
a paradigm shift in the treatment of this debilitating disease. Our team is looking forward to reporting longer-
term results in enrolled patients as the trial progresses,” said Dr. Witkowski, principal study investigator.
ABOUT IPITA
The International Pancreas and Islet Transplantation Association aims to serve the pancreas and islet transplant
scientific community in providing a forum for the open exchange of knowledge and expertise in order to
facilitate the advancement of the clinical practice of pancreas and islet transplantation for the treatment of
human diabetes.( https://www.tts.org/ipita/home)
ABOUT THE STUDY
The approved protocol is a Phase I/II non-randomized, unblinded, single arm, company-sponsored trial, where
diabetic subjects with hypoglycemia unawareness enroll into the study. Participants are then implanted with
Cell Pouches. Following the development of vascularized tissue chambers within the Cell Pouch, subjects are
then stabilized on immunosuppression, and a dose of purified islets, under strict release criteria, is
transplanted into the Cell Pouch.
A sentinel pouch is removed for an early assessment of the islet transplant. Subjects will be followed for
additional safety and efficacy measures for approximately six months. At this point, a decision will be made
with regards to the transplant of a second islet dose with subsequent safety and efficacy follow up. Patients will
then be further followed for one year. The primary objective of the study is to demonstrate safety and
tolerability of islet transplantation into the Cell Pouch. The secondary objective is to assess efficacy through a
series of defined measures.
For more information on this clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939. For more
information on enrollment and recruitment details please visit www.pwitkowski.org/sernova.
ABOUT SERNOVA CORP.
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e. human donor cells, corrected human cells and stem-cell derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent
diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or
hormones missing or in short supply within the body. For more information, please visit www.sernova.com
For further information contact:
United States:
Danny Matthews
Solebury Trout
Tel: (646) 378-2928
dmatthews@soleburytrout.com
www.soleburytrout.com
For investor inquiries and media inquiries in Canada:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
Ray Matthews & Associates
Tel: (604) 818-7778
ray@raymatthews.ca
www.raymatthews.ca
FORWARD-LOOKING INFORMATION
This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,
“believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions
“will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of
future performance, and actual results may differ materially from those in forward-looking statements.
Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the
date such statements were made, which include our beliefs about the conduct and outcome of clinical trials.
Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements
whether as a result of new information, future events or otherwise.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - June 27, 2019 27 June, 2019
Sernovas Principal Investigator to Present Interim Data from the Companys Ongoing Phase I/II Cell Pouch Clinical Trial at the 17th World Congress of the International Pancreas and Islet Transplant Association
June 27, 2019 9:00 a.m. EDT
LONDON, ONTARIO – June 27, 2019 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF), a clinical-stage
regenerative medicine company is pleased to announce that Dr. Piotr Witkowski, Director of Pancreatic, and
Islet Transplant Program at the University of Chicago, will present, in an oral podium session, early preliminary
data and observations from Sernova’s ongoing clinical trial, entitled A Safety, Tolerability and Efficacy Study of
Sernova's Cell Pouch™ for Clinical Islet Transplantation, at the 17th World Congress of the International
Pancreas and Islet Transplantation Association (IPITA) which is being held July 2 – 5, 2019 in Lyon, France.
Dr. Witkowski is scheduled to deliver his address during a symposium on islet transplantation on July 3, 2019
at 10:45 a.m. (CET) at Lyon’s Catholic University in the Amphitheater Merieux 1 & 2. Further details on the
scientific program can be found on the conference website (http://www.ipita2019.org/programme-scientifique).
ABOUT IPITA
The International Pancreas and Islet Transplantation Association aims to serve the pancreas and islet transplant
scientific community in providing a forum for the open exchange of knowledge and expertise in order to
facilitate the advancement of the clinical practice of pancreas and islet transplantation for the treatment of
human diabetes.(https://www.tts.org/ipita/home)
ABOUT SERNOVA’S CLINICAL TRAIL
Sernova is conducting a Phase I/II non-randomized, unblinded, single arm, company-sponsored trial, to assess
the safety and tolerability of islet transplantation into the company’s patented Cell Pouch in diabetic subjects
with hypoglycemia unawareness. The secondary objective is to assess efficacy through a series of defined
measures.
Eligible subjects are implanted with Cell Pouches. Following development of vascularized tissue chambers
within the Cell Pouch, subjects are then stabilized on immunosuppression and a dose of purified islets, under
strict release criteria, transplanted into the Cell Pouch.
A sentinel pouch is removed for an early assessment of the islet transplant. Subjects are followed for additional
safety and efficacy measures for approximately six months. At this point, a decision will be made with regards
to the transplant of a second islet dose with subsequent safety and efficacy follow up. Patients will be then
further followed for one year to assess longer-term safety and efficacy.
For more information on this clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939. For more
information on enrollment and recruitment details please visit www.pwitkowski.org/sernova.
ABOUT SERNOVA CORP.
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e. human donor cells, corrected human cells and stem-cell derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent
diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or
hormones missing or in short supply within the body. For more information, please visit www.sernova.com
For further information contact:
United States:
Danny Matthews
Solebury Trout
Tel: (646) 378-2928
dmatthews@soleburytrout.com
www.soleburytrout.com
For investor inquiries and media inquiries in Canada:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
Ray Matthews & Associates
Tel: (604) 818-7778
ray@raymatthews.ca
www.raymatthews.ca
FORWARD-LOOKING INFORMATION
This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,
“believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions
“will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of
future performance, and actual results may differ materially from those in forward-looking statements.
Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the
date such statements were made, which include our beliefs about the conduct and outcome of clinical trials.
Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements
whether as a result of new information, future events or otherwise.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - May 21, 2019 21 May, 2019
Sernova Corp Announces Appointment of Deborah Brown to its Board of Directors
May 21, 2019 9:00 a.m. EST
LONDON, ONTARIO – May 21, 2019 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) a clinical-stage
regenerative medicine company, today announced the appointment of Ms. Deborah Brown to its Board of
Directors.
Ms. Brown has extensive leadership experience with more than 20 years in senior management roles at a
number of pharmaceutical companies and currently serves as a Managing Partner at Accelera Canada Ltd. She
served as President of EMD Serono, a division of Merck KGaA, Executive Vice President at Serono US, General
Manager, Director of Marketing, and Business Unit Director at Serono Canada and Manager, International
Regulatory at Pasteur Merieux Connaught. Ms. Brown is a former Board Chair of Rx&D (now Innovative
Medicines Canada) and as a Director of the Board, oversaw the 100th anniversary of the association and the
launch of the Canadian Innovation Timeline promoting the contributions Canadian researchers have made to
the discovery and advancement of life science research. Ms. Brown is also a former board member of
BIOTECanada. Ms. Brown holds an MBA from Ivey School of Business. She sits on the board of several
corporate and not-for-profit organizations, including Life Sciences Ontario and the Hamilton/Burlington SPCA.
“Deborah’s nomination comes at an important time as we expand the breadth and experience surrounding
Sernova to help support our clinical development programs, regulatory affairs, R&D, and business
development strategy,” said Mr. Frank Holler, Sernova’s Board Chair. “We’d also like to thank Bruce Weber,
who is stepping down as a director, for his positive contributions to Sernova during his seven years as Board of
Director member.”
Management resolutions at the AGM were approved by a majority of shareholders who voted, including the
election of the directors, Frank Holler (chair), James Parsons, Deborah Brown, Jeffrey Bacha, and Philip
Toleikis; approval of the stock option plan and amendments and approval of Davidson and Co. LLP as
Sernova’s auditor. Additionally, the TSX Venture Exchange (the “Exchange”) has accepted the Plan for filing, as
approved by shareholders at the AGM.
About Sernova Corp
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e. human donor cells, corrected human cells and stem-cell derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent
diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or
hormones missing or in short supply within the body. For more information, please visit www.sernova.com
For further information contact:
United States:
Danny Matthews
Solebury Trout
Tel: (646) 378-2928
dmatthews@soleburytrout.com
www.soleburytrout.com
For investor inquiries and media inquiries in Canada:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
Ray Matthews & Associates
Tel: (604) 818-7778
ray@raymatthews.ca
www.raymatthews.ca
Forward-Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,
“believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions
“will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of
future performance, and actual results may differ materially from those in forward-looking statements.
Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the
date such statements were made, which include our beliefs about the conduct and outcome of clinical trials.
Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements
whether as a result of new information, future events or otherwise.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - April 30, 2019 30 April, 2019
Sernova Announces Collaboration to Advance Therapeutic Cell Pouch Technologies for the Treatment of Hypothyroidism
Co-investigators, Dr. Sam Wiseman of the University of British Columbia and Sernova Corp awarded the
prestigious Transplant Research Foundation of British Columbia Venture Grant
April 30, 2019; 9:00 a.m. EST
LONDON, ONTARIO – April 30, 2019 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF), a clinical-stage
regenerative medicine company announced today a collaboration with the University of British Columbia’s, Dr.
Sam Wiseman for development of a Cell Therapy-based Program for the treatment of hypothyroidism. This
collaboration is funded by a Transplant Venture Grant awarded by the Transplant Research Foundation (TRF)
of British Columbia.
“The only current option for treatment of patients following thyroidectomy, to ensure avoidance of
hypothyroidism, is administration of life-long daily thyroid medication, with intermittent blood testing and
adjustment of medication dosing,” said Dr. Sam Wiseman, thyroid surgeon and researcher, and the Director of
Research in the Department of Surgery at Providence Healthcare in Vancouver. “We hypothesize that through
transplantation into Sernova’s vascularized Cell Pouch, the function of the thyroid gland may be preserved, and
dependence on thyroid medication avoided. This approach is exciting because it could offer patients a cell
therapy option for preservation of their gland function.”
According to the American Thyroid Association (ATA), 20 million Americans currently live with thyroid disease,
and 12% of Americans will develop a thyroid condition during their lifetime. The thyroid gland produces and
secretes thyroid hormone that is essential for life because it serves to regulate the entire body’s metabolism.
The thyroid gland affects all critical body functions including heart rate, energy levels, and the rate at which
energy is produced from nutrients. Loss of thyroid function, or hypothyroidism, may occur spontaneously, or
due to partial or complete removal of the thyroid gland by operation (thyroidectomy).
“The cell-based treatment of hypothyroid disease following thyroidectomy represents a third significant clinical
application including type-1 diabetes and hemophilia further validating Sernova’s Cell Pouch platform
technologies in significant potential markets,” said Dr. Philip Toleikis, President and CEO of Sernova. “The
development of a regenerative medicine approach for these chronic diseases is becoming a reality. In this case
of thyroid disease, successful transplantation of thyroid tissue into Sernova’s cell pouch would represent a
major advance in treatment of this very common problem.”
Thyroidectomy is commonly performed for cancer diagnosis or treatment, as well as for treatment of benign
(non-cancerous) disease that includes goiter and hyperthyroidism. It is estimated that about 150,000
thyroidectomies are performed in the US yearly, and the majority of individuals undergoing a thyroid operation
will be diagnosed with benign disease after their operation. Patients with Grave’s disease and thyroid nodules
undergoing total thyroidectomy, and many patients undergoing partial thyroidectomy require life-long thyroid
hormone medication. Post-surgical thyroid hormone replacement therapy, if monitored carefully, can be
effective; however, patients often suffer from side effects including weight gain, depression, headaches, and
cardiovascular disease, with resultant negative impact on quality of life, and costs to the healthcare system.
Sernova’s approach in the treatment of hypothyroid disease is to transplant healthy thyroid cells of patients
undergoing thyroidectomy into the pre-implanted vascularized Cell Pouch. Currently, pre-clinical proof-of-
concept work is underway. The collaboration will accelerate Sernova’s research efforts and set the stage for the
preparation of a regulatory submission for future clinical assessment of people suffering from hypothyroid
disease with the aim to preserve thyroid function and improve patient quality of life.
In other news, Sernova has been invited to present at the 2019 Bloom Burton & Co. Healthcare Investment
Conference, being held at the Metro Toronto Convention Centre, in Toronto on April 30 and May 1st. Sernova
President and CEO, Dr. Philip Toleikis will speak to its latest corporate presentation and US Phase I/II Human
Clinical Trial at 4:00 PM EDT, on Wednesday, May 1st.
About Sernova Corp.
Sernova, Corp., (TSX-V: SVA) is a clinical stage (US FDA; Health Canada) company, developing disruptive
platform technologies to treat chronic diseases through a regenerative medicine approach. Sernova’s primary
focus is in developing technologies for the treatment of patients with insulin-dependent (TI) diabetes,
hemophilia A and thyroid disease. Sernova is developing regenerative medicine therapeutic technologies using
a medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells and
stem-cell derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases
such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases such as
hypothyroid disease treated through replacement of proteins or hormones missing or in short supply within the
body.
For further information contact:
United States
Danny Matthews,
Senior Associate, Solebury Trout
Tel: (646) 378-2928
dmatthews@soleburytrout.com
www.soleburytrout.com
For investor inquiries and media inquiries in Canada:
Dominic Gray
Corporate Communications
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
Ray Matthews & Associates
Tel: (604) 818-7778
ray@raymatthews.ca
www.raymatthews.ca
Forward-Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,
“believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions
“will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of
future performance, and actual results may differ materially from those in forward-looking statements.
Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the
date such statements were made, which include our beliefs about the conduct and outcome of pre-clinical
results and clinical trials. Sernova expressly disclaims any intention or obligation to update or revise any
forward-looking statements whether as a result of new information, future events or otherwise.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - April 11, 2019 11 April, 2019
Sernova Announces First Transplantation of Therapeutic Cells in Cell Pouch for the Company Phase I/II U.S. Clinical Study for Diabetes
April 11, 2019, 9:00 a.m. EDT
LONDON, ONTARIO – April 11, 2019 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF), a clinical-stage
regenerative medicine company today announced the first Cell Pouch™ transplant of insulin-producing cells in
its U.S. Phase I/II clinical trial evaluating the safety and efficacy of the Cell Pouch for Clinical Islet
Transplantation in type 1 diabetes.
“Sernova’s Cell Pouch technologies are positioned to provide the most severe patients with improved, long
term options to manage their diabetes,” said Dr. Piotr Witkowski, Clinical Trial Principal Investigator and
Director of the Pancreatic Islet Transplant Program at the University of Chicago. “The current standard of care,
involves islet transplants into the portal vein which has significant limitations including the development of an
immediate blood-mediated inflammatory reaction (IBMIR), limited supply of donor organs and the challenges in
isolating and obtaining a consistent quality of islet preparations.”
In accordance with the study protocol, the Cell Pouch was implanted prior to transplant of purified islets. This
procedure enables the development of vascularized tissue chambers and provides an interval for patient
stabilization on standard immune protection medications. Prior to transplantation, the Cell Pouch was
assessed for safety. A Sentinel Pouch, a small monitoring device, was also transplanted with islets. In
accordance with the protocol the Sentinel Pouch will be removed approximately 90 days post-transplant to
assess islet survival as an interim indicator of efficacy.
“Sernova’s Cell Pouch provides a non-fibrosing, vascularized environment for the transplantation of therapeutic
cells, to enhance the curative potential of islet transplantation and other cell therapies,” said Dr. Philip Toleikis,
President and CEO of Sernova. “We are thrilled with Dr. Witkowski’s progress as well as his decision to move
forward with transplantation based on his analysis of the safety and vascularization of the Cell Pouch.”
“This important clinical milestone advances our Cell Pouch technologies as a valuable enabling foundation for
cell therapies across a range of indications including type 1 diabetes, hemophilia and thyroid disease,” added
Dr. Toleikis.
The Company is expecting to report preliminary safety data from Sernova’s clinical study in the first half of
2019 and preliminary efficacy data in the second half of 2019.
About the Study
The approved protocol is a Phase I/II non-randomized, unblinded, single arm, company-sponsored trial, where
diabetic subjects with hypoglycemia unawareness enroll into the study under informed consent. Participants
are then implanted with Cell Pouches. Following the development of vascularized tissue chambers within the
Cell Pouch, subjects are then stabilized on immunosuppression, and a dose of purified islets, under strict
release criteria, is transplanted into the Cell Pouch.
A sentinel pouch will be removed for an early assessment of the islet transplant. Subjects will be followed for
additional safety and efficacy measures for approximately six months. At this point, a decision will be made
with regards to the transplant of a second islet dose with subsequent safety and efficacy follow up. Patients will
then be further followed for one year. The primary objective of the study is to demonstrate the safety and
tolerability of islet transplantation into the Cell Pouch. The secondary objective is to assess efficacy through a
series of defined measures.
For more information on this clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939. For more
information on enrollment and recruitment details please visit www.pwitkowski.org/sernova.
About Hypoglycemia Unawareness and Diabetes
Type 1 diabetes is a chronic disease that affects more than 42.5 million globally, in which the body's immune
system attacks and destroys the pancreatic cells that produce insulin, an essential hormone to help the body
use glucose. To date, there is no cure for type 1 diabetes, and people living with the disease are dependent on
insulin therapy, an imperfect treatment method that requires careful monitoring throughout the day along with
multiple calculated doses of insulin to help regulate their blood sugar levels. A miscalculation or unexpected
variable leading to high or low blood sugar episodes are daily threats, and only a third of people with type 1
diabetes achieve their long-term blood glucose targets, placing them at risk for type 1 diabetes-related health
complications. Hypoglycemia unawareness, a subset of diabetes in which individuals experience a critical drop
in blood sugar without warning symptoms, represents more than 15% of type 1 diabetes population.
About the Cell Pouch
The Cell Pouch is a novel, proprietary, scalable, implantable macro-encapsulation device designed for the
long-term survival and function of therapeutic cells. The device is designed to incorporate with tissue, forming
highly vascularized tissue chambers for the transplantation and function of therapeutic cells which then release
proteins and hormones as required to treat disease. The device along with therapeutic cells has been shown to
provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to
provide a biologically compatible environment for insulin-producing cells in humans.
About Sernova Corp
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e. human donor cells, corrected human cells and stem-cell derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent
diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or
hormones missing or in short supply within the body. For more information, please visit www.sernova.com
For further information contact:
United States:
Danny Matthews
Solebury Trout
Tel: (646) 378-2928
dmatthews@soleburytrout.com
www.soleburytrout.com
Canada:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
Ray Matthews & Associates
Tel: (604) 818-7778
ray@raymatthews.ca
www.raymatthews.ca
Forward-Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,
“believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions
“will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of
future performance, and actual results may differ materially from those in forward-looking statements.
Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the
date such statements were made, which include our beliefs about the conduct and outcome of clinical trials.
Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements
whether as a result of new information, future events or otherwise.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - February 11, 2019 11 February, 2019
Sernova Corp Announces First Patient Implanted with Sernova Cell Pouch in a Phase I/II US Clinical Trial for the Treatment of Hypoglycemia Unawareness in Subjects with Type 1 Diabetes
February 11, 2019; 9:00 a.m. EST
LONDON, ONTARIO – February 11, 2019 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF), a clinical-stage
regenerative medicine company today announced the first patient implanted with Sernova’s Cell Pouch™ in the
Phase I/II clinical trial evaluating the safety and efficacy of Sernova’s Cell Pouch™ for Clinical Islet
Transplantation in type 1 diabetes.
“Islet transplantation has shown success as a therapeutic option for treating patients with hypoglycemia
unawareness; the most unstable, high-risk form of type 1 diabetes. Given the limited supply of donor islet
cells, it is imperative to develop approaches that capitalize on a more efficient use of donor islet cells,” said Dr.
Piotr Witkowski principal investigator and Director of the Pancreatic and Islet Transplant Program at University
of Chicago School of Medicine. “We believe Sernova’s Cell Pouch creates a vascularized environment, rich in
microvessels that will allow robust engraftment and extended survival of the transplanted islet cells. We hope
this will result in the need for fewer transplants per patient and, ultimately, create a long-term treatment option
for patients suffering from hypoglycemic unawareness.”
Cell Pouches, including, small sentinel pouches were implanted. Following development of the vascularized
tissue chambers, and stabilization on immune protection medications, the Cell Pouch will be transplanted with
donor islet cells. Approximately 90-days after transplant, small sentinel devices are removed to evaluate islet
survival as an initial efficacy endpoint.
“This important clinical milestone represents an exciting time at Sernova as we pursue safe, effective, and
innovative regenerative medicine treatments for patients with hypoglycemia unawareness in type 1 diabetes,”
said Dr. Philip Toleikis, President and CEO of Sernova Corp. “We are confident this US clinical trial will support
and add important data to the positive pre-clinical results of our small and large diabetes animal models, and
our first-in-human trial with Health Canada. It will also contribute to the development of broader applications
for the Cell Pouch including our diabetes stem cell technologies and additional indications.”
The Company is expecting to report preliminary safety data from Sernova’s clinical study in the first half of
2019 and preliminary efficacy data in the second half of 2019.
About the Study
The approved protocol is a Phase I/II non-randomized, unblinded, single arm, company-sponsored trial, where
diabetic subjects with hypoglycemia unawareness enroll into the study under informed consent. Participants
are then implanted with Cell Pouches. Following the development of vascularized tissue chambers within the
Cell Pouch, subjects are then stabilized on immunosuppression, and a dose of purified islets, under strict
release criteria, is transplanted into the Cell Pouch.
A sentinel pouch will be removed for an early assessment of the islet transplant. Subjects will be followed for
additional safety and efficacy measures for approximately six months. At this point, a decision will be made
with regards to the transplant of a second islet dose with subsequent safety and efficacy follow up. Patients will
then be further followed for one year. The primary objective of the study is to demonstrate safety and
tolerability of islet transplantation into the Cell Pouch. The secondary objective is to assess efficacy through a
series of defined measures.
For more information on this clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939 . For
more information on enrollment and recruitment details please visit www.pwitkowski.org/sernova or contact
(773) 702-2504.
About Hypoglycemia Unawareness and Diabetes
Type 1 diabetes is a chronic disease that affects more than 42.5 million globally, in which the body's immune
system attacks and destroys the pancreatic cells that produce insulin, an essential hormone to help the body
use glucose. To date, there is no cure for type 1 diabetes, and people living with the disease are dependent on
insulin therapy, an imperfect treatment method that requires careful monitoring throughout the day along with
multiple calculated doses of insulin to help regulate their blood sugar levels. A miscalculation or unexpected
variable leading to high or low blood sugar episodes are daily threats, and only a third of people with type 1
diabetes achieve their long-term blood glucose targets, placing them at risk for type 1 diabetes-related health
complications. Hypoglycemia unawareness, a subset of diabetes in which individuals experience a critical drop
in blood sugar without warning symptoms, represents more than 15% of type 1 diabetes population.
About the Cell Pouch
The Cell Pouch is a novel, proprietary, scalable, implantable macro-encapsulation device designed for the
long-term survival and function of therapeutic cells. The device is designed to incorporate with tissue, forming
highly vascularized tissue chambers for the transplantation and function of therapeutic cells which then release
proteins and hormones as required to treat disease. The device along with therapeutic cells has been shown to
provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to
provide a biologically compatible environment for insulin-producing cells in humans.
About Sernova Corp
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e. human donor cells, corrected human cells and stem-cell derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin- dependent
diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or
hormones missing or in short supply within the body. For more information, please visit www.sernova.com
For further information contact:
United States: Danny Matthews Solebury Trout Tel: (646) 378-2928 dmatthews@soleburytrout.com
www.soleburytrout.com
For investor inquiries and media inquiries in Canada:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
Ray Matthews & Associates
Tel: (604) 818-7778
ray@raymatthews.ca
www.raymatthews.ca
Forward-Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,
“believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions
“will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of
future performance, and actual results may differ materially from those in forward-looking statements.
Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the
date such statements were made, which include our beliefs about the conduct and outcome of clinical trials.
Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements
whether as a result of new information, future events or otherwise.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - January 30, 2019 30 January, 2019
Sernova Announces the Appointment of Dr. David Lillicrap, M.D. to its Scientific Advisory Board
Sernova Adds Scientific Advisory Board Expertise as it Broadens its Therapeutic Cell Therapy Applications for
Rare Blood Diseases
January 30, 2019 9:00 a.m. EST
LONDON, ONTARIO – January 30, 2019 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) a clinical-stage
regenerative medicine company, today announced the appointment of Dr. David Lillicrap, M.D., FRCPC to its
Scientific Advisory Board (SAB).
Dr. David Lillicrap is Associate Head, Research, and Professor in the Department of Pathology and Molecular
Medicine at Queen's University at Kingston, Ontario, Canada. He holds a Tier 1 Canada Research Chair (CRC)
in Molecular Hemostasis and is a past Career Investigator of the Heart and Stroke Foundation of Ontario. In
2013, he was elected to the Fellowship of the Royal Society of Canada. Dr. Lillicrap serves as a member of the
Medical Advisory Board of the World Federation of Hemophilia. He is a member of the Council of the
International Society on Thrombosis and Haemostasis (ISTH), is a past Chair of ISTH’s Scientific and
Standardization Committee and is Co-Editor-in-Chief of the Society’s journal, the Journal of Thrombosis and
Haemostasis. Dr. Lillicrap has also been a SAB member of the Horizon 2020 HemAcure program developing a
personalized medicine approach for treatment of hemophilia of which Sernova is partner. He is an
internationally recognized expert on the molecular basis of common inherited bleeding disorders.
“We are pleased to welcome David to Sernova’s Scientific Advisory Board,” said Dr. Philip Toleikis President
and CEO Sernova Corp. “Dr. Lillicrap’s internationally recognized leadership in hematology and novel cell and
gene therapy-based applications will be instrumental as we expand the breadth and experience of our Scientific
Advisory Board in support of Sernova’s hemophilia and other rare disease programs.”
As a Canada Research Chair in Molecular Hemostasis, his program of research focuses on the molecular basis
of the hemostatic system (coagulation), with a particular emphasis on the commonest inherited bleeding
disorders, hemophilia, and von Willebrand disease. During his tenure as a Canada Research Chair, Dr.
Lillicrap’s group has achieved several research accomplishments including the establishment of a national
reference laboratory for the genetic diagnosis of inherited bleeding disorders. His research interests focus on
three key areas including von Willebrand factor pathobiology, factor VIII immunology and the evaluation of
novel gene, and cell-based strategies for the treatment of hemophilia.
About the Cell Pouch System
The Cell Pouch is a novel, proprietary, scalable, implantable macro-encapsulation device designed for the long-
term survival and function of immune protected therapeutic cells. The device is designed to incorporate with
tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells
which then release proteins and hormones as required to treat disease. The device along with therapeutic cells
has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has
been proven to provide a biologically compatible environment for insulin-producing cells in humans. Within the
Horizon 2020 HemAcure program corrected human cells from subjects with Hemophilia A have been shown to
engraft within the Cell Pouch, produce Factor VIII and improve blood clotting in a preclinical model of
hemophilia A.
About Sernova Corp
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e. human donor cells, corrected human cells and stem-cell derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent
diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or
hormones missing or in short supply within the body. For more information, please visit www.sernova.com
For further information contact:
United States:
Danny Matthews
Solebury Trout
Tel: (646) 378-2928
dmatthews@soleburytrout.com
www.soleburytrout.com
For investor inquiries and media inquiries in Canada:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
Ray Matthews & Associates
Tel: (604) 818-7778
ray@raymatthews.ca
www.raymatthews.ca
Forward-Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,
“believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions
“will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of
future performance, and actual results may differ materially from those in forward-looking statements.
Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the
date such statements were made, which include our beliefs about the conduct and outcome of clinical trials.
Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements
whether as a result of new information, future events or otherwise.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - January 28, 2019 28 January, 2019
Sernova to Participate on Diabetes Panel and Present at NobleConXV, 15th Annual Investor Conference January 28th - 29th, 2019
January 28, 2019 6:00 a.m. EST
LONDON, ONTARIO – January 28, 2019 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical-
stage regenerative medicine company announced today that Dr. Philip Toleikis, President and CEO will present
the latest company overview and is invited to participate on the Diabetes Panel at NobleConXV — Noble
Capital Markets’ Fifteenth Annual Investor Conference at the W Hotel in Fort Lauderdale, Fla., on Monday
January 28th at 11:00 a.m. Eastern Time.
The panel will cover a broad spectrum of interests involving diabetes including the discovery and
commercialization of novel diabetes therapeutics and diagnostics, diabetes research, as well as nutrition and
awareness. Included on the panel are Dr. Camillo Ricordi, Director of the Diabetes Research Institute; Dr.
Michael Castagna, CEO of MannKind Corporation; Steve Perrin, Ph.D., CEO and Founder of Anelixis
Therapeutics; William L. Rust, Ph.D., CEO and Founder of Seraxis; Michael Fox of DugalHealth; Martin Beland,
VP Marketing and Strategic Development of Inolife Sciences; Steve Glover, CEO of Variant Pharmaceuticals;
and Dr. Philip Toleikis, Ph.D., President & CEO of Sernova Corp.
A video webcast of the presentation will be available the following day on the company's website
www.sernova.com and as part of a complete catalog of presentations available at Noble Capital Markets’
Conference website (http://nobleconference.com) as well as on the new investor portal created by Noble called
Channelchek (http://www.channelchek.com).
About Sernova, Corp
Sernova, Corp., (TSX-V: SVA) is a clinical stage (US FDA; Health Canada) company, developing disruptive
platform technologies to treat chronic diseases through a regenerative medicine approach. Sernova’s primary
focus is in developing technologies for the treatment of patients with insulin-dependent (TI) diabetes,
hemophilia A and thyroid disease. Sernova is developing regenerative medicine therapeutic technologies using a
medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells and
stem-cell derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases
such as insulin- dependent diabetes, blood disorders including hemophilia, and other diseases treated through
replacement of proteins or hormones missing or in short supply within the body.
For further information contact:
Danny Matthews, Senior Associate
Solebury Trout
Tel: (646) 378-2928
dmatthews@soleburytrout.com
www.soleburytrout.com
For investor inquiries and media inquiries in Canada:
Dominic Gray, Corporate Communications
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
Ray Matthews & Associates
Tel: (604) 818-7778
ray@raymatthews.ca
www.raymatthews.ca
Forward-Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,
“believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions
“will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of
future performance, and actual results may differ materially from those in forward-looking statements.
Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the
date such statements were made, which include our beliefs about the conduct and outcome of clinical trials.
Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements
whether as a result of new information, future events or otherwise.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - January 17, 2019 17 January, 2019
Sernova Announces Successful Enrollment Approaching 50% of Subjects in its U.S. Phase I/II Cell Pouch Diabetes Clinical Trial
January 17, 2019 9:00 a.m. EST
LONDON, ONTARIO – January 17, 2019 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF), a clinical-stage
regenerative medicine company today announced the enrollment of the first three of seven subjects in its Phase
I/II trial of Sernova’s Cell Pouch™ for Clinical Islet Transplantation in type 1 diabetes.
“We are pleased to report we are on track with patient enrollment in the Sernova Cell Pouch study for type 1
diabetes,” stated Dr. Piotr Witkowski, principal investigator and Director of the Pancreatic and Islet Transplant
Program at University of Chicago School of Medicine. “The Cell Pouch System is designed to improve the
quality of life of people with diabetes and this milestone marks an important step towards building further
validation of Sernova’s innovative approach to diabetes treatment.”
Sernova is expecting to report preliminary safety data from this landmark clinical study in the first half of 2019
and preliminary efficacy data in the second half of 2019.
About the Study
The FDA allowed protocol is a Phase I/II non-randomized, open label, single arm, company-sponsored trial,
where up to seven diabetic subjects with hypoglycemia unawareness enroll into the study under informed
consent. The primary objective of the study is to demonstrate safety and tolerability of islet transplantation
into the Cell Pouch. The secondary objective is to assess efficacy through a series of defined measures including
reduction in severe hypoglycemic events and HbA1c as well as survival of islets following transplant into the
Cell Pouch.
Study subjects will receive Sernova’s Cell Pouches including a small sentinel device implanted under the skin.
Following a defined period to allow for the development of vascularized tissue chambers within the Cell Pouch,
subjects will be stabilized on immunosuppression, and a dose of purified islets, under strict release criteria, will
be transplanted into the Cell Pouch.
The sentinel Cell Pouch will be removed after approximately 90 days to allow for an early assessment of islet
survival in the device. Subjects will be followed for additional safety and efficacy measures for approximately
six months. At this point, a decision will be made with regard to the transplant of a second dose of purified
islets. Patients will then be further followed to assess safety and efficacy for up to one year.
For more information on this clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939. For more
information on enrollment and recruitment details please visit www.pwitkowski.org/sernova or contact (773)
702-2504.
About Diabetes
Type 1 diabetes is a chronic disease that affects more than 42.5 million globally, in which the body's immune
system attacks and destroys the pancreatic cells that produce insulin, an essential hormone to help the body
use glucose. To date, there is no cure for type 1 diabetes, and people living with the disease are dependent on
insulin therapy, an imperfect treatment method that requires careful monitoring throughout the day along with
multiple calculated doses of insulin to help regulate their blood sugar levels. A miscalculation or unexpected
variable leading to high or low blood sugar episodes are daily threats, and only a third of people with type 1
diabetes achieve their long-term blood glucose targets, placing them at risk for type 1 diabetes-related health
complications. Hypoglycemia unawareness, a subset of diabetes in which individuals experience a critical drop
in blood sugar without warning symptoms, represents more than 15% of type 1 diabetes population.
About the Cell Pouch
The Cell Pouch is a novel, proprietary, scalable, implantable macro-encapsulation device designed for the long-
term survival and function of therapeutic cells. The device is designed to incorporate with tissue, forming highly
vascularized tissue chambers for the transplantation and function of therapeutic cells which then release
proteins and hormones as required to treat disease. The device along with therapeutic cells has been shown to
provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to
provide a biologically compatible environment for insulin-producing cells in humans.
About Sernova Corp
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e. human donor cells, corrected human cells and stem-cell derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent
diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or
hormones missing or in short supply within the body. For more information, please visit www.sernova.com
For further information contact:
United States:
Danny Matthews
Solebury Trout
Tel: (646) 378-2928
dmatthews@soleburytrout.com
www.soleburytrout.com
Canada:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
Ray Matthews & Associates
Tel: (604) 818-7778
ray@raymatthews.ca
www.raymatthews.ca
Forward-Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,
“believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions
“will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of
future performance, and actual results may differ materially from those in forward-looking statements.
Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the
date such statements were made, which include our beliefs about the conduct and outcome of clinical trials.
Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements
whether as a result of new information, future events or otherwise.
Contact Us Contactez-nous
Business
development
Développement
des affaires
Dr. Philip Toleikis
Sernova Corp.
1.519.858.5184
info@sernova.com
Corporate
communications
Communication
d'entreprise
Dominic Gray
Sernova, Corp.
1.519.858.5126
info@sernova.com
About UsL'entreprise
Company OverviewPrésentation de l'entreprise
LeadershipDirection
PartnersLes partenaires
Company MilestonesJalons de l'entreprise
Corporate GovernanceGouvernance d'Entreprise
TechnologyTechnologie
Regenerative MedicineMédecine régénérative
Cell Pouch System™Cell Pouch System™
Immune Protection TechnologyImmuno-Protection
IndicationsLes Indications
Therapeutic PipelinePipeline Thérapeutique
Clinical StudiesEtudes cliniques
PressPresse
Featured NewsNouvelles
Press ReleasesCommuniqués de presse
Latest UpdatesDernières mises à jour
News Dispatch ServiceService de Distribution de Nouvelles
InvestorInvestisseur
Financial ReportsRapports Financiers
EventsÉvénements
Analyst Coverage Couverture d'analyste
Stock PricePrix de l'action
About Sernova.com A propos de Sernova.com
Sernova Corp (TSX-V: SVA) is a clinical stage (US FDA; Health Canada) company, developing disruptive platform technologies to treat chronic diseases through a regenerative medicine approach. Sernova’s primary focus is in developing technologies for the treatment of patients with insulin-dependent (TI) diabetes, hemophilia A and thyroid disease. Sernova Corp (TSX-V: SVA) est une société en phase clinique (US FDA; Santé Canada) développant des applications thérapeutiques afin de traiter les maladies chroniques grâce à une approche régénérative. L’objectif principal de Sernova est de développer des technologies pour le traitement des patients atteints de diabète insulino-dépendant (T1), d’hémophilie A et de maladie de la glande thyroïde.
Please read our Legal Notice and Privacy Policy which includes information about Disclaimers and Terms of Use. Veuillez lire notre notice légale et notre politique de confidentialité, qui comprennent des informations sur les clauses de non-responsabilité et les conditions d'utilisation.
Career OpportunitiesOpportunités de carrière
See our latest job posting and long-term career opportunities: Voir nos dernières offres d'emploi et opportunités de carrière à long terme:
Career Opportunities pagePage web Opportunités de carrière
Follow us Suivez nous
All content is copyright
Tout le contenu est copyright
© 2001 - 2019 Sernova, Corp.
All content is copyright Tout le contenu est copyright © 2001 - 2019 Sernova, Corp.